title: Blinded independent central review of the progression-free survival endpoint.
authors.affiliation: GlaxoSmithKline, Collegeville, Pennsylvania, USA.
authors.forename: Ohad
authors.initials: O
authors.lastname: Amit
authors.forename: Will
authors.initials: W
authors.lastname: Bushnell
authors.forename: Lori
authors.initials: L
authors.lastname: Dodd
authors.forename: Nancy
authors.initials: N
authors.lastname: Roach
authors.forename: Daniel
authors.initials: D
authors.lastname: Sargent
mesh_terms: D017326:Clinical Trials, Phase III as Topic / Q000592:standards*; D003625:Data Collection; D018572:Disease-Free Survival; D004311:Double-Blind Method; D023381:Endpoint Determination; D006801:Humans; D008485:Medical Audit / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D016896:Treatment Outcome